Arvinas

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

CEO

John G. Houston

CEOJohn G. Houston

Employees

430

Employees430

Headquarters

New Haven, Connecticut

HeadquartersNew Haven, Connecticut

Founded

2013

Founded2013

Employees

430

Employees430

ARVN Key Statistics

Market cap

478.68M

Market cap478.68M

Price-Earnings ratio

-1.27

Price-Earnings ratio-1.27

Dividend yield

—

Dividend yield—

Average volume

2.41M

Average volume2.41M

High today

$6.73

High today$6.73

Low today

$6.44

Low today$6.44

Open price

$6.63

Open price$6.63

Volume

548.60K

Volume548.60K

52 Week high

$29.61

52 Week high$29.61

52 Week low

$5.90

52 Week low$5.90

ARVN News

Seeking Alpha 6d

Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes

Earnings Call Insights Arvinas signals CEO transition and extends cash runway into H2 2028 amid vepdeg collaboration changes Aug. 06, 2025 1:24 PM ET Arvinas, I...

Seeking Alpha 6d

Arvinas GAAP EPS of -$0.84 beats by $0.10, revenue of $22.4M misses by $12.02M

Earnings News Arvinas GAAP EPS of -$0.84 beats by $0.10, revenue of $22.4M misses by $12.02M Aug. 06, 2025 7:22 AM ET Arvinas, Inc. (ARVN) Stock By: Meghavi Sin...

Analyst ratings

56%

of 18 ratings

Buy

55.6%

Hold

44.4%

Sell

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.